Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 746 participants.
Also called NCT02738879
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 746 participants
- Sponsor
- Registry
-
NCT02738879 -
2015-004990-34
-
- Other papers using this trial's data
- Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02738879. Randomized; double masking; primary purpose treatment. Start 2016-05-09 (actual); primary completion 2018-01-22 (actual). Results posted on 2019-02-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Sitagliptin Withdrawal Study (MK-0431-845)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo to sitagliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Metformin XR
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02738879- Content hash
78446d12d697ec1309bc4161ccf741354355f787d539ed2542cfcfd0029446eb